Rigel Pharmaceuticals (RIGL) Enterprise Value (2010 - 2026)

Rigel Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$146.7 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 90.25% year-over-year to -$146.7 million in Q1 2026; TTM through Mar 2026 was -$146.7 million, a 90.25% decrease from a year earlier, with the FY2025 full-year figure at -$155.0 million, down 100.4% from the prior year.
• Enterprise Value advanced to -$146.7 million in Q1 2026 per RIGL's latest filing, from -$155.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$49.1 million in Q2 2024 and bottomed at -$155.0 million in Q4 2025.
• The 5-year median for Enterprise Value is -$77.1 million (2025), against an average of -$84.7 million.
• Biggest YoY gain for Enterprise Value was 53.42% in 2022; the steepest drop was 173.27% in 2022.
• Year by year, Enterprise Value stood at -$58.2 million in 2022, then increased by 2.19% to -$56.9 million in 2023, then slumped by 35.81% to -$77.3 million in 2024, then sank by 100.4% to -$155.0 million in 2025, then increased by 5.34% to -$146.7 million in 2026.
• Per Business Quant, the three latest RIGL Enterprise Value figures stand at -$146.7 million (Q1 2026), -$155.0 million (Q4 2025), and -$137.1 million (Q3 2025).